CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
Gemcitabine, and S-1drug
Likely dose
Gemcitabine, and S-1 1000 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02146703
NCT02146703Phase 2Completed
CompareCT.gov

Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer

Hallym University Medical Center·interventional·Posted May 26, 2014·Updated May 26, 2014

In Brief

A Phase 2 clinical trial evaluating Gemcitabine, and S-1 for Biliary Tract Neoplasm. Completed, enrolled 38 participants across 1 site.

Detailed Summary

This study will conduct a phase II study of gemcitabine and S-1 as first-line chemotherapy in patient with advanced biliary tract cancer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBiliary Tract Neoplasm
CountriesSouth Korea
CollaboratorsJeil Pharmaceutical Co., Ltd.

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 26, 2014
Enrollment StartAug 1, 2005
Primary CompletionNov 1, 2010
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 12.1 years ago

Interventions

Gemcitabine, and S-1drug

Treatment will be delivered as a 3-week cycle. 1. Gemcitabine 1000 mg/m2 iv on day 1, 8 2. S-1 60 mg/day po on day 1-14